It’s the latest step from pharmacy benefit managers to respond to relentless criticism from politicians and regulators over prescription drug costs.

Sees FY25 adjusted revenue at least $252,000. Sees FY25 capital expenditures $1.4B. Sees FY25 effective tax rate 19%. The company said, “The

UnitedHealthcare's legal drug dealing arm is, according to the government, massively marking up the cost of life-saving medications.

An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare Foundation (AHF) and independent pharmacies. | Prime Therapeutics, a PBM owned by Blue Cross plans,

Cigna’s Express Scripts called the report “another set of misleading conclusions based on a subset of medications that represent less than 2% of what our health plans spend on medications in a year” and said the FTC had failed to address the ...

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their prices by hundreds — and in some cases, thousands — of percent, resulting in $7.3 billion in revenue above cost.

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Strawberry Hills Pharmacy owner Daniel Jones reacted Thursday to a recent Federal Trade Commission report which showed pharmacy benefit managers made billions of dollars by inflating the price of drugs.

The lawsuit – which has been anticipated since the FTC published a damning report on the PBM sector in July – names CVS Health's Caremark, UnitedHealth Group's Optum, and Cigna's Express ...

As the rising cost of insulin continues to make it difficult for so many diabetic patients to receive life-saving care, Insulin Outlet is stepping up to help by providing safe, affordable, and accessible insulin to those who need it most.

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation and patient access to treatments.

Reports Q4 revenue $65.65B, consensus $63.18B. “While higher medical costs in our stop loss product impacted fourth quarter earnings, we are